Download full text PDF

T. Simankova; A. Balashova; O. Arisheva, Candidate of Medical Sciences; I. Garmash, Candidate of Medical Sciences; Professor V. Moiseev, MD, Academician of the Russian Academy of Sciences Peoples’ Friendship University of Russia, Moscow

The efficacy and safety of the NS3/4A protease inhibitor simeprevir were investigated in difficult-to-treat patients with HCV infection.

hepatitis C
protease inhibitors

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Perz J., Armstrong G., Farrington L. et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide // J. Hepatol. – 2006; 45 (4): 529–38.
  2. Lopatkina T.N. Hronicheskij gepatit S: vnepechenochnye projavlenija, osobennosti klinicheskogo techenija, diagnostika // Virusnye gepatity: inf. bjull. – 2000; 2 (3): 5–6.
  3. World Health Organization. Global Alert and Response: Hepatitis C. http:/
  4. Deuffic-Burban S., Babany G., Lonjon-Domanec I. et al. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France // Hepatology. – 2009; 50: 1351–9.
  5. Drenth J. HCV Treatment – No More Room for Interferonologists? // N. Engl. J. Med. – 2013; 368: 1931–2.
  6. Kuntzen T., Timm J., Berical A. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-napve patients // Hepatology. – 2008; 48 (6): 1769–78.
  7. McHutchison J., Everson G., Gordon S. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection // N. Engl. J. Med. – 2009; 360: 1827–38.
  8. Romano K., Ali A., Schiffer C. Avoiding drug resistance against HCV NS3/4A protease inhibitors. [abstract 17] // Antiviral Therapy. – 2010; 15 (Suppl. 2): A1–A189.
  9. FDA Approves Incivek (telaprevir) for People with Hepatitis C / Vertex Press Releases, 2011.
  10. Alessio Agherno. 24-th Conference of Asian Pacific Association for the Study of the Liver (APASL) / Istanbul, Turkey, 2015.
  11. Heim M. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end // Nat. Rev. Immunol. – 2013; 13: 535–42.
  12. Jacobson I., McHutchision J., Dusheiko G. et al. Telaprevir for previousiy untreated chronic hepatitis C virus infection // N. Engl. J. Med. – 2011; 364 (25): 2405–16.
  13. Poordad F., McCone J. Jr., Bacon B. et al. Boceprevir for untreated chronic HCV genotip 1 infection // N. Engl. J. Med. – 2011; 364 (13): 1195–206.
  14. You D., Pockros P. Simeprevir for the treatment of chronic hepatitis C // Expert Opin. Pharmacother. – 2013; 14 (18): 2581–9.
  15. Jacobson I. SVR results of a once-daily regimen of simeprevir (TMC-438) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Program and abstracts of American Association for the Study of Liver Diseases The Liver Meeting®. 2013. Abstract LB-3.
  16. Forns X., Lawitz E., Zeuzem S. et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial // Gastroenterology. – 2014; 146: 1669–79.
  17. Jacobson I., Dore G., Foster G. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial // Lancet. – 2014; 384: 403–13.
  18. Manns M., Marcellin P., Poordad F. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial // Lancet. – 2014; 384: 414–26.
  19. Reddy K., Zeuzem S., Zoulim F. et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial // Lancet Infect. Dis. – 2015; 15: 27–35.
  20. EASL Recommendations on Treatment of Hepatitis C 2015 // J. Hepatol. – 2015; 63: 199–236.
  21. Ledinghen V., Vergniol J. Transient elastography (FibroScan) // Gastrœntérol. Clin. Bio. – 2008; 32: 58–67.
  22. D’Ambrosio R., Aghemo A., Fraquelli M. et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response // J. Hepatol. – 2013; 59: 251–6.
  23. Vergniol J., Foucher J., Terrebonne E. et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C // Gastroenterology. – 2011; 140: 1970–9.
  24. Lontok E., Harrington P., Howe A. et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary // Hepatology. – 2015; 62 (5): 1623–32. doi: 10.1002/hep.27934. Epub 2015 Jul 30.
  25. Lenz O., Verbinnen T., Fevery B. et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies // J. Hepatol. – 2015; 62 (5): 1008–14. doi: 10.1016/j.jhep.2014.11.032. Epub 2014 Nov. 28.